July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.
June 24, 2021: Effect of efavirenz metabolism on weight change; determinants of weight gain when switching meds; metabolic effects of DTG vs. TAF; food security vs. nutrition security.
May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.
Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.
Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds
Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
May 14, 2020: Recurring low-level viremia and morbidity/mortality risk; factors affecting severe bacterial infection in people with HIV; infective endocarditis cases on the rise; high rates of opioid use among U.S. veterans with HIV.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.